Edelinontrine
As of the edition of 20 October 2026, Edelinontrine is a small molecule: stopped in 2023; acts on PDE9A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 9, 2 stopped early
- Disease areas
- Heart and blood vessels; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Edelinontrine.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE9A | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | O76083 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2008 to now |
| Cardurion Pharmaceuticals | Lead sponsor of trials | 2022 to now |